Sartorius

EQS-News: Resolutions of the Annual General Meeting of Sartorius AG

Retrieved on: 
Wednesday, April 10, 2024
Sartorius AG, Sartorius, Annual general meeting, PwC, Supervisory board

At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share.

Key Points: 
  • At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share.
  • This press release contains forward-looking statements about the future development of the Sartorius Group.
  • Sartorius assumes no liability for updating such statements in light of new information or future events.
  • Sartorius shall not assume any liability for the correctness of this translation.

Labroots to Host the 6th Annual Bioprocessing Virtual Event Series on April 3rd, 2024

Retrieved on: 
Thursday, March 28, 2024
University at Albany, SUNY, State university system, Analytic, Sartorius, Research, Downstream processing, Science News, BioLegend, Bioprocess, University, Drug discovery, Carbohydrate, Immortalised cell line, Biology, Quality, Labroots, Cell, Molecular biology, Eppendorf

YORBA LINDA, Calif., March 28, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific networking website and producer of educational virtual events and webinars, is thrilled to announce the 6th Annual Bioprocessing Virtual Event Series, scheduled for April 3rd, 2024. This free, day-long online event will bring together experts and enthusiasts from around the globe to delve into the latest advancements and topics in bioprocessing.

Key Points: 
  • YORBA LINDA, Calif., March 28, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific networking website and producer of educational virtual events and webinars, is thrilled to announce the 6th Annual Bioprocessing Virtual Event Series , scheduled for April 3rd, 2024.
  • This free, day-long online event will bring together experts and enthusiasts from around the globe to delve into the latest advancements and topics in bioprocessing.
  • Labroots leverages the Chati virtual event platform to offer an interactive, immersive educational digital experience.
  • Participants can use the official hashtag #LRbioprocessing to follow the conversation and connect with other members in the Bioprocessing community!

Labroots Announces its 8th Annual Laboratory Automation Virtual Event, Scheduled on March 20, 2024

Retrieved on: 
Thursday, March 14, 2024
Automaton, Automation, Receptor, Almost, Q&A, Cell, Protein, Laboratory automation, MIT, LIMS, Sartorius, CDS, Research, Science News, WEI, Media lab, Science, Doctor of Philosophy, Networking hardware, Laboratory, Cytokine, CRISPR, Immortalised cell line, Labroots, Molecular biology, Medicine, UCLA, Antigen

YORBA LINDA, Calif., March 14, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website, offering premier, interactive virtual events and webinars, is delighted to host its 8th annual Laboratory Automation online event on March 20, 2024. This free event brings together thousands of research scholars, scientists, and laboratory personnel from leading academic and industry institutions under a virtual roof to explore scientific disciplines with sessions spanning microfluidic and microscale technologies for automation, automation and emerging methods, lab automation with cutting-edge tools, LIMS and other automation software, and analytics for high-throughput and high content assays.

Key Points: 
  • YORBA LINDA, Calif., March 14, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website, offering premier, interactive virtual events and webinars, is delighted to host its 8th annual Laboratory Automation online event on March 20, 2024.
  • The insightful agenda encompasses leading-edge advancements aimed at automating and accelerating research, and amplifying efficiency in the lab.
  • A lively Q&A session, following the presentation sponsored by Automata titled, "How to Prepare for Lab Automation."
  • Participants can use the official hashtag #LRlabauto to follow the conversation and connect with other members in the Laboratory Automation community!

EQS-News: Sartorius releases Annual Report for 2023

Retrieved on: 
Friday, February 16, 2024
Acquisition, Quality control, Sartorius, Laboratory, Annual report, Research, Vaccine

The life science group Sartorius has released its Annual Report for 2023 today.

Key Points: 
  • The life science group Sartorius has released its Annual Report for 2023 today.
  • Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing.
  • Sartorius regularly expands its portfolio through the acquisition of complementary technologies.
  • In 2023, the company generated sales revenue of around 3.4 billion euros.

Labroots Announces Agenda for its 7th Annual Drug Discovery & Development Virtual Event on February 21, 2024

Retrieved on: 
Thursday, February 15, 2024
Neuroscience, Toxicity, Doctor of Philosophy, FCCP, Lactation, FCP, Spectrum, Fear, Labroots, Associate, Anxiety, Networking hardware, Oxytocin, G protein-coupled receptor, Tumor microenvironment, QIAGEN, Drug discovery, Therapy, Digital image, DSM-IV codes, Thermo Fisher Scientific, Advantage Business Media, Laboratory, Miltenyi Biotec, Doctor of Pharmacy, MPS, Safety, Biomarker, Beta-lactam, Sartorius, Regulation, Master of Science, Merck, Epithelial–mesenchymal transition, Dean (education), Lung cancer, Cancer, Pharmaceutical industry

YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series. Hosted on February 21st and free to attend, attendees will experience the forefront of pharmaceutical innovation joining industry and academic leaders from around the world debating the latest, insightful scientific breakthroughs in this ever-evolving field.

Key Points: 
  • Focusing from pre-clinical development to clinical development, advances in the field of drug discovery and development will be explored shaping current and future challenges in drug research
    YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series .
  • The 2024 informative agenda covers a range of sessions spanning areas including Emerging Modalities in Drug Discovery and Preclinical Development, New Methods in Pharmacogenomics, and Biomarker Applications.
  • Use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.

EQS-News: The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share

Retrieved on: 
Friday, February 9, 2024
Sartorius, Supervisory board, Annual, Research, Vaccine, Sartorius AG, Laboratory, Acquisition, Quality control, Security (finance)

The Supervisory Board of Sartorius AG resolved at its meeting today to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 28, 2024, to pay a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share for fiscal 2023.

Key Points: 
  • The Supervisory Board of Sartorius AG resolved at its meeting today to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 28, 2024, to pay a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share for fiscal 2023.
  • Under this proposal, the total distributed profit would be 50.7 million euros.
  • This press release contains forward-looking statements about the future development of the Sartorius Group.
  • Sartorius assumes no liability for updating such statements in light of new information or future events.

EQS-News: Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028

Retrieved on: 
Tuesday, January 30, 2024
CO2, Patient, Deleveraging, Forecasting, Research, Sartorius, Face, Electricity, Novasep, Public expenditure, Acquisition, Sartorius AG, Acceleration, Transfection, Weakness, Vaccine, News, Growth

Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)

Key Points: 
  • Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • Sales revenue in the Americas region was down 14.9 percent and accounted for around 38 percent of the Group total.
  • In the Asia | Pacific region, in particular, the pronounced weakness of the market in China had a significant impact, with sales revenue down 22.1 percent.
  • Sartorius intends to continue its profitable growth path in the long term and expects to grow faster than the market.

Vaccine Partner Valneva receives FDA approval for the World's first chikungunya vaccine using Albumedix' Recombumin®

Retrieved on: 
Wednesday, November 22, 2023
Chikungunya, Vaccine, LTD, Research, Safety, Viral disease, Mosquito-borne disease, Sartorius, Temperature, FDA, Pharmaceutical industry

NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus. Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.

Key Points: 
  • Valneva's lyophilized chikungunya vaccine IXCHIQ® is the first in the world to be FDA approved against the viral disease, addressing an unmet medical need.
  • Recombumin®, a chemically defined, human and animal origin-free recombinant human albumin, is a critical enabler for the manufacture and formulation of Valneva's chikungunya vaccine.
  • NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus.
  • Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.

Vaccine Partner Valneva receives FDA approval for the World's first chikungunya vaccine using Albumedix' Recombumin®

Retrieved on: 
Wednesday, November 22, 2023
Chikungunya, Vaccine, LTD, Research, Safety, Viral disease, Mosquito-borne disease, Sartorius, Temperature, FDA, Pharmaceutical industry

NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus. Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.

Key Points: 
  • Valneva's lyophilized chikungunya vaccine IXCHIQ® is the first in the world to be FDA approved against the viral disease, addressing an unmet medical need.
  • Recombumin®, a chemically defined, human and animal origin-free recombinant human albumin, is a critical enabler for the manufacture and formulation of Valneva's chikungunya vaccine.
  • NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus.
  • Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.

Labroots Announces Agenda for its 14th Annual Clinical Diagnostics & Research Online Event - held on November 8th, 2023

Retrieved on: 
Monday, November 6, 2023
Linda, TBI, Q&A, Pathology, Medical laboratory, Clinical professor, Workplace, Research, Sartorius, Dietary supplement, Mass spectrometry, Ortho Clinical Diagnostics, Roche, Networking hardware, Medicine, Labroots, Greeting, LR, Personalized medicine, Melissa Chaty, Thermo Fisher Scientific, Diversity, Lab, Patient, Mayo Clinic, Medical device, Nursing, News, Clinical

YORBA LINDA, Calif., Nov. 6, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 14th annual event in the Clinical Diagnostics & Research Virtual Event Series scheduled on November 8, 2023. This event will continue its long-standing commitment to advance clinical diagnostics, novel research and medicine, and to align research scholars, clinicians, top scientists, healthcare professionals and experts from leading academia and industry institutions under a virtual roof on a global basis.

Key Points: 
  • YORBA LINDA, Calif., Nov. 6, 2023 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 14th annual event in the Clinical Diagnostics & Research Virtual Event Series scheduled on November 8, 2023.
  • Attendees will also see multiple panels and presentations from key industry sponsors including, Sartorius, Thermo Fisher Scientific, and Roche Diagnostics.
  • Use the hashtag #LRclinical to follow the conversation and connect with other members of the global Clinical & Molecular Dx Community!
  • Join our Clinical & Molecular Dx Interest Group on LinkedIn to connect with us, and the wider professional community!